€72.80
0.14%
Borsa Italiana, Oct 16, 05:35 pm CEST. Closed.
ISIN
IT0005274094
Symbol
PHN

Pharmanutra Stock price

€72.80
-4.40 5.70% 1M
-8.90 10.89% 6M
+18.50 34.07% YTD
+24.30 50.10% 1Y
+23.85 48.72% 3Y
+4.40 6.43% 5Y
+58.87 422.77% 10Y
+58.87 422.77% 20Y
Borsa Italiana, Closing price Fri, Oct 16 2026
-0.10 0.14%
ISIN
IT0005274094
Symbol
PHN

Is Pharmanutra a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,109 stocks worldwide.

Key metrics

Basic
Market capitalization
€699.0m
Enterprise Value
€702.2m
Net debt
€3.2m
Cash
€15.1m
Shares outstanding
9.6m
Valuation
P/E
24.1
P/S | estimate
3.4 | 4.5
EV/Sales | estimate
3.4 | 4.5
EV/FCF | ex SBC
46.8 | -
P/B
10.0
Dividends
DPS
€1.20
Yield 1Y | 5Y
1.7% | 1.5%
Growth 1Y | 5Y
20.0% | 12.4%
Payout 1Y | 3Y
47.9% | 51.5%
Increased
9 Years
Financials
Revenue | estimate
€208.2m | €156.2m
EBITDA
€49.3m
EBIT
€44.1m
Net Income
€29.0m
Free Cash Flow | ex SBC
€15.0m | -
Growth
Revenue | estimate
18.9% | 18.6%
EBITDA
13.8%
EBIT
15.2%
Net Income
22.9%
Free Cash Flow
83.4%
Margin
Gross
95.3%
EBITDA
23.7%
EBIT
21.2%
Net
13.9%
Free Cash Flow | ex SBC
7.2% | -
Financial Health
Equity Ratio
57.0%
Return on Equity
28.0%
ROCE
50.7%
ROIC
36.5%
Debt/Equity
0.3
More
EPS
€3.0
FCF per Share
€1.6
Short interest
-
Employees
128
Rev per Employee
€1.0m

Pharmanutra Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Pharmanutra forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Pharmanutra forecast:

Buy
86%
Hold
14%

Financial data from Pharmanutra

Jun '26
+/-
%
208 208
19% 19%
100%
- Direct Costs 9.77 9.77
89% 89%
5%
198 198
17% 17%
95%
- Selling and Administrative Expenses 149 149
20% 20%
71%
- Research and Development Expense 1.41 1.41
6% 6%
1%
49 49
14% 14%
24%
- Depreciation and Amortization 5.16 5.16
3% 3%
2%
EBIT (Operating Income) EBIT 44 44
15% 15%
21%
Net Profit 29 29
23% 23%
14%

In millions EUR.

Don't miss a Thing! We will send you all news about Pharmanutra directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.

Head office Italy
Employees 128
Website www.pharmanutra.it

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today